Sweden · Delayed Price · Currency is SEK Carasent AB Earnings Call Transcripts
Fiscal Year 2026
-
Q2 saw robust recurring revenue growth, improved profitability, and strong cash flow, bolstered by the InfoSolutions acquisition and cost savings. AI and product innovation continue to drive customer wins, while regulatory and market dynamics shape adoption pace and pricing.
-
ARR grew 16% year-over-year with strong profitability and 19% growth in the Nordics, while German revenues declined due to legacy churn. AI-driven product enhancements and Medsum adoption are key growth drivers, with share buybacks and targeted acquisitions planned.
Fiscal Year 2025
-
Q4 saw 15% organic ARR growth, a 16% EBITDA margin, and strong profitability, driven by major client migrations and high consulting revenues. AI investments continue, with Medsom now using OpenAI, and the sales pipeline remains robust, especially in the Nordics.
-
Q3 saw 16% organic ARR growth, 29% EBITDA margin, and strong cost control, with major product rollouts in Germany and Scandinavia. Revenue timing in Q4 depends on key project implementations, while SEK 70 million was spent on share buybacks, leaving a SEK 170 million cash balance.
-
Revised targets reflect project delays, restructuring, and increased AI investment, but ARR and recurring revenue continue to grow. Key wins in Västra Götaland and strong AI product development support a positive outlook, though execution risks remain.
-
EBITDA margin turned positive to 6% and revenue grew 29% year-over-year, driven by strong organic and acquired growth. AI investments and receivable write-downs slightly increased costs, but cash flow and ARR remain robust. Focus continues on growth, efficiency, and targeted M&A.
Fiscal Year 2024
-
Q4 saw strong ARR and margin growth, driven by the Data-Al acquisition and operational efficiency. One-off churn from bankruptcies will impact Q1/Q2, but underlying growth remains robust, with large contracts set to convert to revenue in autumn.
-
The acquisition of Data-AL enables immediate entry into Germany's large, fragmented EHR market, leveraging local expertise and a stable customer base. The deal is expected to drive revenue growth through cloud migration, with integration and commercial rollout of Webdoc X planned over the next few years.
-
Q3 saw strong organic growth, improved EBITDA, and higher gross margins, with robust contract wins and a positive outlook for continued expansion. One-time costs from relisting and acquisitions impacted results, but cost control and efficiency measures are driving profitability.
-
Recurring revenue grew 15% year-over-year, with major new contracts and improved margins. Adjusted EBITDA margin doubled to 16%, and positive cash flow was achieved. Strong growth is expected from new product launches and German expansion.